Literature DB >> 34760564

Pre-eclampsia and long-term cardiac dysfunction: A review of asymptomatic cardiac changes existing well beyond the post-partum period.

Archana S Thayaparan1, Joanne M Said2, Sandra A Lowe3, Anthony McLean4, Yang Yang5.   

Abstract

BACKGROUND: Pre-eclampsia is a disease of pregnancy characterised by the manifestations of multi-organ dysfunction. The recent use of transthoracic echocardiography in the assessment of women with pre-eclampsia has allowed the detection of cardiac systolic and diastolic dysfunction in the acute phase. Women with a history of pre-eclampsia also have increased lifelong risks of cardiovascular disease and mortality that persists well beyond the post-partum period. These developments raise the possibility that pre-eclampsia may be an early marker of cardiovascular disease and the potential role for echocardiography in guiding the detection and management of this. This review aims to summarise the existing evidence of echocardiographic cardiac assessment of women with a history of pre-eclampsia performed more than 12 weeks post-partum.
METHODS: A systematic search of PubMed and OVID EMBASE databases was performed to identify studies featuring assessment of cardiac function performed after 12 weeks post-partum in women with a history of pre-eclampsia. Studies without post-partum cardiac assessment or with other documented causes for cardiomyopathy were excluded.
RESULTS: Thirteen studies were identified that measured cardiac function by transthoracic echocardiography between 6 months and 18 years following a pregnancy complicated by pre-eclampsia. Common findings across the studies were of increased diastolic dysfunction, increased left ventricular mass index (LVMI) and concentric hypertrophy in women with a history of pre-eclampsia, as compared to women with uncomplicated pregnancy histories. This was predominantly seen in those with a history of early or preterm pre-eclampsia.
CONCLUSIONS: Women with a history of early or preterm pre-eclampsia have an increased prevalence of diastolic dysfunction. This review demonstrates that the cardiac dysfunction associated with previous pre-eclampsia is quantifiable and persistent. Progression of heart failure from asymptomatic to symptomatic stages carries a fivefold increase in mortality. The use of echocardiography could detect cardiac dysfunction in the asymptomatic stage and guide more intensive risk factor modification in these women.
© 2019 Australasian Society for Ultrasound in Medicine.

Entities:  

Keywords:  cardiac; echocardiography; heart disease; pregnancy; pre‐eclampsia; ultrasound

Year:  2019        PMID: 34760564      PMCID: PMC8411796          DOI: 10.1002/ajum.12173

Source DB:  PubMed          Journal:  Australas J Ultrasound Med        ISSN: 1836-6864


  31 in total

1.  Maternal cardiac dysfunction and remodeling in women with preeclampsia at term.

Authors:  Karen Melchiorre; George Ross Sutherland; Aigul Baltabaeva; Marco Liberati; Basky Thilaganathan
Journal:  Hypertension       Date:  2010-11-22       Impact factor: 10.190

Review 2.  Risk of cardiovascular disease after pre-eclampsia and the effect of lifestyle interventions: a literature-based study.

Authors:  D Berks; M Hoedjes; H Raat; J J Duvekot; E A P Steegers; J D F Habbema
Journal:  BJOG       Date:  2013-03-26       Impact factor: 6.531

3.  Post-partum evaluation of maternal cardiac function after severe preeclampsia.

Authors:  Tullio Ghi; Daniela Degli Esposti; Elisa Montaguti; Martina Rosticci; Francesca De Musso; Aly Youssef; Ginevra Salsi; Gianluigi Pilu; Claudio Borghi; Nicola Rizzo
Journal:  J Matern Fetal Neonatal Med       Date:  2013-09-18

4.  Cardiac structure and function, and ventricular-arterial interaction 11 years following a pregnancy with preeclampsia.

Authors:  Maha Al-Nashi; Maria J Eriksson; Eva Östlund; Katarina Bremme; Thomas Kahan
Journal:  J Am Soc Hypertens       Date:  2016-01-20

5.  Preeclampsia is associated with persistent postpartum cardiovascular impairment.

Authors:  Karen Melchiorre; George Ross Sutherland; Marco Liberati; Basky Thilaganathan
Journal:  Hypertension       Date:  2011-08-15       Impact factor: 10.190

6.  Use and Limitations of E/e' to Assess Left Ventricular Filling Pressure by Echocardiography.

Authors:  Jae-Hyeong Park; Thomas H Marwick
Journal:  J Cardiovasc Ultrasound       Date:  2011-12-27

7.  The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.

Authors:  Alessandro Liberati; Douglas G Altman; Jennifer Tetzlaff; Cynthia Mulrow; Peter C Gøtzsche; John P A Ioannidis; Mike Clarke; P J Devereaux; Jos Kleijnen; David Moher
Journal:  PLoS Med       Date:  2009-07-21       Impact factor: 11.069

8.  Hypertension after preeclampsia is preceded by changes in cardiac structure and function.

Authors:  Chahinda Ghossein-Doha; Louis Peeters; Sanne van Heijster; Sander van Kuijk; Julia Spaan; Tammo Delhaas; Marc Spaanderman
Journal:  Hypertension       Date:  2013-06-03       Impact factor: 10.190

Review 9.  The global impact of pre-eclampsia and eclampsia.

Authors:  Lelia Duley
Journal:  Semin Perinatol       Date:  2009-06       Impact factor: 3.300

Review 10.  Shared biomarkers between female diastolic heart failure and pre-eclampsia: a systematic review and meta-analysis.

Authors:  Lisa J Alma; Anouk Bokslag; Angela H E M Maas; Arie Franx; Walter J Paulus; Christianne J M de Groot
Journal:  ESC Heart Fail       Date:  2017-01-30
View more
  2 in total

Review 1.  Hypertensive Disorders of Pregnancy and Heart Failure Risk.

Authors:  Sarah A Goldstein; Neha J Pagidipati
Journal:  Curr Hypertens Rep       Date:  2022-03-28       Impact factor: 4.592

2.  Incidence of essential hypertension but not echocardiographic abnormalities at four years with a history of preeclampsia with severe features.

Authors:  Arthur Jason Vaught; Anum Minhas; Theresa Boyer; Alexia Debrosse; Garima Sharma; Dhananjay Vaidya; Pamela Ouyang; Sammy Zakaria; Monica Mukherjee
Journal:  Pregnancy Hypertens       Date:  2021-06-12       Impact factor: 2.899

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.